As someone in the field, distribution would be a nightmare initially. You have to consider manufacturing, regulations, and training for administering the cure. Ideally, it would prioritize terminal and late-stage patients. And let's not forget the economic ramifications; healthcare systems would save, but pharmaceutical companies could lose big. It's a …